4-benzyl-quinazoline | 92437-11-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-benzyl-quinazoline
• 英文别名: 4-Benzylquinazoline
• CAS: 92437-11-1
• 化学式: C₁₅H₁₂N₂
• 分子量: 220.274
• InChiKey: POAJSIAXCGAHAE-UHFFFAOYSA-N

物化性质

• 沸点：
  375.0±11.0 °C(Predicted)
• 密度：
  1.162±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-氰基-4H-喹唑啉-3-羧酸乙酯 在 氢氧化钾 、 sodium hydride 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 4-benzyl-quinazoline
  参考文献：
  名称：

  Kant, Joydeep; Popp, Frank D.; Uff, Barrie C., Journal of Heterocyclic Chemistry, 1985, vol. 22, p. 1313 - 1316

  摘要：

  DOI：

文献信息

• Carbon-Carbon Bond Cleavage of .ALPHA.-Hydroxybenzylheteroarenes Catalyzed by Cyanide Ion: Retro-Benzoin Condensation Affords Ketones and Heteroarenes and Benzyl Migration Affords Benzylheteroarenes and Arenecarbaldehydes.
  作者：Yumiko SUZUKI、Yuki TAKEMURA、Ken-ichi IWAMOTO、Takeo HIGASHINO、AKira MIYASHITA

  DOI：10.1248/cpb.46.199

  日期：——

  4-(α-Benzyl-α-hydroxybenzyl)quinazoline (4a) underwent retro-benzoin condensation catalyzed by cyanide ion to give deoxybenzoin (2a) and quinazoline (5a). Similarly, several nitrogen-containing heteroarenes (4, 9, 12, 16-19) having an α-hydroxybenzyl group at the α-position of the nitrogen underwent retro-benzoin type condensation to afford ketones (2) and heteroarenes (5). However, similar reaction of pyrazolopyrimidines (13, 14, 15) having an α-benzyl-α-hydroxybenzyl group resulted in benzyl migration, giving benzylpyrazolopyrimidines (8) and arenecarbaldehydes (3). Tetrabutylammonium cyanide (11, Bu4NCN) was a more effective cyanide ion donor than KCN (10). The retro-benzoin condensation was applied to the synthesis of 2-substituted quinazolines (38) from 2-chloro-4-aroylquinazolines (34), using the aroyl group as a protecting and electron-withdrawing group.

  4-(α-苄基-α-羟基苄基)喹唑啉(4a)在氰离子催化下经历逆苯偶姻缩合反应，生成脱氧苯偶姻(2a)和喹唑啉(5a)。同样，多个含氮杂环芳烃(4, 9, 12, 16-19)在其氮原子的α位上具有α-羟基苄基的结构，也经历逆苯偶姻型缩合反应，生成了酮(2)和杂环芳烃(5)。然而，具有α-苄基-α-羟基苄基结构的吡唑嘧啶(13, 14, 15)在类似的反应中引发了苄基迁移，生成了苄基吡唑嘧啶(8)和芳烃羰醛(3)。四丁基铵氰(11, Bu4NCN)比KCN(10)更有效地作为氰离子的供体。逆苯偶姻缩合反应被应用于从2-氯-4-芳酰基喹唑啉(34)合成2-取代喹唑啉(38)，使用芳酰基作为保护和电子 withdrawing 基团。
• Spiro compounds and methods of use
  申请人：Chen Paul Guoqing

  公开号：US20070167470A1

  公开（公告）日：2007-07-19

  The present invention relates to spiro compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states such as cancers associated with protein tyrosine kinases, especially epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), to their method of use as medicaments and to their method of use in the manufacture of medicaments for use in the production of inhibition of tyrosine kinase reducing effects in warm-blooded animals such as humans.

  本发明涉及式I的螺环化合物，其制备方法，含有其作为活性成分的药物组合物，用于治疗与蛋白酪氨酸激酶相关的疾病状态，特别是表皮生长因子（EGF）和血管内皮生长因子（VEGF）相关的癌症等疾病状态的方法，以及它们作为药物的使用方法，以及用于制造用于在温血动物（如人类）中减少酪氨酸激酶抑制效果的药物的使用方法。
• Quinazoline derivatives
  申请人：Ple Patrick

  公开号：US20090233924A1

  公开（公告）日：2009-09-17

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及公式（I）的喹唑啉衍生物或其药学上可接受的盐、溶剂或前药，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个都具有在本说明书中定义的任何含义；制备它们的过程，含有它们的制药组合物以及它们用于制造用于治疗细胞增殖性疾病或与血管生成和/或血管通透性相关的疾病状态的药物的用途。
• QUINAZOLINE DERIVATIVES
  申请人：Ple Patrick

  公开号：US20120165351A1

  公开（公告）日：2012-06-28

  The invention concerns quinazoline derivatives of Formula I or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  该发明涉及公式I的喹唑啉衍生物，或其药学上可接受的盐、溶剂或前药，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个具有上述描述中定义的任何含义；其制备过程，含有它们的药物组合物以及它们在制造用于治疗细胞增殖性疾病或与血管生成和/或血管通透性相关的疾病状态的药物中的使用。
• Spiro Compounds And Methods Of Use
  申请人：CHEN GUOQING PAUL

  公开号：US20110237794A1

  公开（公告）日：2011-09-29

  The present invention relates to spiro compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states such as cancers associated with protein tyrosine kinases, especially epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), to their method of use as medicaments and to their method of use in the manufacture of medicaments for use in the production of inhibition of tyrosine kinase reducing effects in warm-blooded animals such as humans.

  本发明涉及式I的螺环化合物、其制备方法、含有其作为活性成分的药物组合物、用于治疗与蛋白酪氨酸激酶相关的癌症等疾病状态的方法，特别是表皮生长因子（EGF）和血管内皮生长因子（VEGF），以及它们作为药物的使用方法和用于制造药物的使用方法，用于在温血动物如人类中产生酪氨酸激酶抑制减少效应的生产。